Gone Today, Hair Tomorrow—Follica Raises Funds to Begin Human Trial of Baldness Treatment

Call it a hair-raising event. Follica, a Boston startup out to develop novel ways of treating and even curing baldness and other hair-follicle disorders, today announced it had completed a $5.5 million Series A financing round. The round was led by Interwest Partners of Dallas and Menlo Park, CA, and joined by founding investor PureTech Ventures, in whose offices Follica is currently housed.

Follica was founded in late 2006 by PureTech and a group of leading academics who include Harvard Medical School dermatologist Rox Anderson, University of Pennsylvania stem cell biologist George Cotsarelis, and Vera Price, director of the University of California, San Francisco (UCSF) Hair Research Center. Its primary initial focus is an extremely common form of hair loss called androgenic alopecia—aka male pattern baldness or female pattern baldness.

Follica has targeted a, shall we say, growth industry. According to PureTech’s website, treatments for conditions of the follicle—chief among them hair loss, acne, and pigmentation issues—represent a $10 billion-plus annual market. It’s all part of the even broader category of “aesthetic medicine,” which also includes things like plastic surgery and many obesity treatments. And it is really in the recognition of the potential of aesthetic medicine that the, um, roots of Follica’s story lie.

Daphne Zohar, PureTech’s founder and managing partner (and an Xconomist), says the firm began thinking seriously about aesthetic medicine in early 2006. “There’s huge markets, and most of the technologies and things that are out there don’t come from real academic science,” she says. “A lot of them are this late-night infomercial type of thing.” But the market potential is undeniable, and it wasn’t lost on Zohar that people pay out of pocket for aesthetic treatments, meaning no health insurance reimbursement issues for manufacturers to contend with.

PureTech put together a team of expert advisors to begin looking at different aspects of aesthetic medicine. Their survey spanned everything from skin rejuvenation approaches to fat melting techniques, perhaps more than 100 different ideas in all, Zohar says. “As we were looking, we noticed the most interesting things

Author: Robert Buderi

Bob is Xconomy's founder and chairman. He is one of the country's foremost journalists covering business and technology. As a noted author and magazine editor, he is a sought-after commentator on innovation and global competitiveness. Before taking his most recent position as a research fellow in MIT's Center for International Studies, Bob served as Editor in Chief of MIT's Technology Review, then a 10-times-a-year publication with a circulation of 315,000. Bob led the magazine to numerous editorial and design awards and oversaw its expansion into three foreign editions, electronic newsletters, and highly successful conferences. As BusinessWeek's technology editor, he shared in the 1992 National Magazine Award for The Quality Imperative. Bob is the author of four books about technology and innovation. Naval Innovation for the 21st Century (2013) is a post-Cold War account of the Office of Naval Research. Guanxi (2006) focuses on Microsoft's Beijing research lab as a metaphor for global competitiveness. Engines of Tomorrow (2000) describes the evolution of corporate research. The Invention That Changed the World (1996) covered a secret lab at MIT during WWII. Bob served on the Council on Competitiveness-sponsored National Innovation Initiative and is an advisor to the Draper Prize Nominating Committee. He has been a regular guest of CNBC's Strategy Session and has spoken about innovation at many venues, including the Business Council, Amazon, eBay, Google, IBM, and Microsoft.